The Role of Cardiovascular Risk Factors and Stroke in Familial Alzheimer Disease
- PMID: 27533593
- PMCID: PMC5155512
- DOI: 10.1001/jamaneurol.2016.2539
The Role of Cardiovascular Risk Factors and Stroke in Familial Alzheimer Disease
Abstract
Importance: The contribution of cardiovascular disease (CV) and cerebrovascular disease to the risk for late-onset Alzheimer disease (LOAD) has been long debated. Investigations have shown that antecedent CV risk factors increase the risk for LOAD, although other investigations have failed to validate this association.
Objective: To study the contribution of CV risk factors (type 2 diabetes, hypertension, and heart disease) and the history of stroke to LOAD in a data set of large families multiply affected by LOAD.
Design, setting, and participants: The National Institute on Aging Late-Onset Alzheimer Disease/National Cell Repository for Alzheimer Disease family study (hereinafter referred to as NIA-LOAD study) is a longitudinal study of families with multiple members affected with LOAD. A multiethnic community-based longitudinal study (Washington Heights-Inwood Columbia Aging Project [WHICAP]) was used to replicate findings. The 6553 participants in the NIA-LOAD study were recruited from 23 US Alzheimer disease centers with ongoing data collection since 2003; the 5972 WHICAP participants were recruited at Columbia University with ongoing data collection since 1992. Data analysis was performed from 2003 to 2015.
Main outcomes and measures: Generalized mixed logistic regression models tested the association of CV risk factors (primary association) with LOAD. History of stroke was used for the secondary association. A secondary model adjusted for the presence of an apolipoprotein E (APOE) ε4 allele. A genetic risk score, based on common variants associated with LOAD, was used to account for LOAD genetic risk beyond the APOE ε4 effect. Mediation analyses evaluated stroke as a mediating factor between the primary association and LOAD.
Results: A total of 6553 NIA-LOAD participants were included in the analyses (4044 women [61.7%]; 2509 men [38.3%]; mean [SD] age, 77.0 [9] years), with 5972 individuals from the WHICAP study included in the replication sample (4072 women [68.2%]; 1900 men [31.8%]; mean [SD] age, 76.5 [7.0] years). Hypertension was associated with decreased LOAD risk (odds ratio [OR], 0.63; 95% CI, 0.55-0.72); type 2 diabetes and heart disease were not. History of stroke conferred greater than 2-fold increased risk for LOAD (OR, 2.23; 95% CI, 1.75-2.83). Adjustment for APOE ε4 did not alter results. The genetic risk score was associated with LOAD (OR, 2.85; 95% CI, 2.05-3.97) but did not change the independent association of LOAD with hypertension or stroke. In the WHICAP sample, hypertension was not associated with LOAD (OR, 0.99; 95% CI, 0.88-1.11), whereas history of stroke increased the risk for LOAD (OR, 1.96; 95% CI, 1.56-2.46). The effect of hypertension on LOAD risk was also mediated by stroke in the NIA-LOAD and the WHICAP samples.
Conclusions and relevance: In familial and sporadic LOAD, a history of stroke was significantly associated with increased disease risk and mediated the association between selected CV risk factors and LOAD, which appears to be independent of the LOAD-related genetic background.
Conflict of interest statement
Dr Boeve reports serving as an investigator for clinical trials sponsored by Cephalon, Inc, Allon Pharmaceuticals, and GE Healthcare; receiving royalties from the publication of a book titled Behavioral Neurology of Dementia (Cambridge Medicine; 2009); receiving honoraria from the American Academy of Neurology; serving on the Scientific Advisory Board of the Tau Consortium; and receiving research support from the National Institute on Aging (NIA) (grants P50 AG016574, U01 AG006786, RO1 AG032306, RO1 AG041797) and the Mangurian Foundation. Dr Farlow reports receiving grant and research support from Accera, Biogen, Eisai Med Res, Eli Lilly & Company, Genentech, MedAvante/AstraZeneca, and Navidea; serving on the speaker's bureau at Eisai Med Res, Pfizer, Inc, Forest, Novartis, and Eli Lilly & Company; serving on the consultant or advisory boards at Accera, Alltech, Avanir, Eisai Med Res, Inc, Helicon, Medavante, Medivation, Inc, Merck and Co, Inc, Novartis, Pfizer, Inc, Prana Biotech, QR Pharma, Roche, Sanofi-Aventis, Schering-Plough, Toyama Pharm, Eli Lilly & Company, UCB Pharma, and Elan. Dr Rosenberg reports holding a US patent for Amyloid β Gene Vaccines and serving on the editorial board of the Journal of the Neurological Sciences. Disclosures:No other disclosures were reported.
Comment in
-
Association of Cardiovascular Risk Factors and Stroke With Alzheimer Disease.JAMA Neurol. 2017 Jan 1;74(1):128-129. doi: 10.1001/jamaneurol.2016.4381. JAMA Neurol. 2017. PMID: 27842151 No abstract available.
-
Association of Cardiovascular Risk Factors and Stroke With Alzheimer Disease-Reply.JAMA Neurol. 2017 Jan 1;74(1):129-130. doi: 10.1001/jamaneurol.2016.4384. JAMA Neurol. 2017. PMID: 27842174 No abstract available.
References
-
- Citron M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov. 2010;9(5):387–398. - PubMed
-
- Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol. 2001;154(7):635–641. - PubMed
MeSH terms
Grants and funding
- U24 AG021886/AG/NIA NIH HHS/United States
- P50 AG016574/AG/NIA NIH HHS/United States
- U01 AG052411/AG/NIA NIH HHS/United States
- P01 AG007232/AG/NIA NIH HHS/United States
- U24 AG026395/AG/NIA NIH HHS/United States
- P50 AG005133/AG/NIA NIH HHS/United States
- R01 AG041797/AG/NIA NIH HHS/United States
- R01 AG037212/AG/NIA NIH HHS/United States
- RF1 AG015473/AG/NIA NIH HHS/United States
- U24 AG056270/AG/NIA NIH HHS/United States
- R01 AG017917/AG/NIA NIH HHS/United States
- RF1 AG054023/AG/NIA NIH HHS/United States
- S10 OD018522/OD/NIH HHS/United States
- UL1 TR001108/TR/NCATS NIH HHS/United States
- P30 AG010161/AG/NIA NIH HHS/United States
- R01 AG032306/AG/NIA NIH HHS/United States
- U01 AG006786/AG/NIA NIH HHS/United States
- R01 AG015819/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous